A novel non-alcoholic steatohepatitis animal model featured with insulin resistance, hepatic inflammation and fibrosis

Scandinavian Journal of Gastroenterology

Volumn 45, Issue 11, 2010, Pages 1360-1371

  Zhao, Jingmin ^a   Zhou, Guangde ^a   Li, Meirong ^a   Li, Wenshu ^a   Lü, Jiyun ^a   Xiong, Lu ^a   Liang, Li ^a   Zhao, Yulai ^a   Xu, Dongping ^a   Yu, Jun ^b  

^a BEIJING 302 HOSPITAL   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

High fat diet; Inflammation; Insulin resistance; Model of non alcoholic steatohepatitis; Propylthiouracil

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; BETA CHEMOKINE; INTERLEUKIN 6; LEPTIN; PROPYLTHIOURACIL; RESISTIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; HEPATITIS; INFLAMMATION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID DIET; LIVER FIBROSIS; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT;

ADIPONECTIN; ANIMALS; CHEMOKINES; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FATTY LIVER; GENE EXPRESSION REGULATION; HEPATITIS; INSULIN RESISTANCE; LEPTIN; LIVER CIRRHOSIS; MALE; POLYMERASE CHAIN REACTION; RATS; RATS, SPRAGUE-DAWLEY; RESISTIN; RNA; SEVERITY OF ILLNESS INDEX;

EID: 77958468753     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2010.497938     Document Type: Article

References (31)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231
2. Farrell GC, Larter CZ. Non-alcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006;43:S1-12.
3. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty fiver disease a feature of the metabolic syndrome. Diabetes 2001;50: 1844-1850
4. Serfaty L, Lemoine M. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis. Diabetes Metab 2008;34:634-637
5. Malaguarnera M, Di Rosa M, Nicoletti F, Malaguarnera L. Molecular mechanisms involved in NAFLD progression. J Mol Med 2009;87:679-695
6. Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N, Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol 2007; 47:142-156
7. Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 2008;118: 829-838
8. Fong DG, Nehra V, Lindor KD, Buchman AL. Metabolic and nutritional considerations in non-alcoholic fatty liver. Hepatology 2000;32:3-10.
9. Matteoni CA, Younossi ZM, Gramich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419
10. Pagano C, Soardo G, Pilon C, Milocco C, Basan L, Milan G, et al. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab 2006;91:1081-1086
11. Larter CZ, Yeh MM. Animal models of NASH: getting both pathology and metabolic context right. J Gastroenterol Hepatol 2008;23:1635-1648
12. Rizki G, Arnaboldi L, Gabrielli B, Yan J, Lee GS, Ng RK, et al. Mice fed a lipogenic methionine-cholinedeficient diet develop hypermetabolism coincident with suppression of SCD-1. J Lipid Res 2006;47:2280-2290
13. Nakayama H, Otabe S, Ueno T, Hirota N, Yuan X, Fukutani T, et al. Transgenic mice expressing nuclear sterol regulatory element-binding protein 1c in adipose tissue exhibit liver histology similar to nonalcoholic steatohepatitis. Metabolism 2007;56:470-475
14. Carmiel-Haggai M, Cederbaum AI, Nieto N. A high-fat diet leads to the progression of non-alcoholic fatty liver disease in obese rats. FASEB 2005;19:136-138
15. Deng Q, She H, Cheng JH, French SW, Koop DR, Xiong S, et al. Steatohepatitis induced by intragastric overfeeding in mice. Hepatology 2005;42:905-914
16. Rinella ME, Green RM. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol 2004;40:47-51.
17. Rinella ME, Elias MS, Smolak RR, Fu T, Borensztajn J, Green RM. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res 2008;49:1068-1076
18. Haffner SM, Miettinen H, Stern MP. The homeostasis model in the San Antonio Heart Study. Diabetes Care 1997;20:1087-1092
19. Davalli AM, Ogawa Y, Scaglia L, Wu YJ, Hollister J, Bonner-Weir S, et al. Function, mass, and replication of porcine and rat islets transplanted into diabetic nude mice. Diabetes 1995;44:104-111
20. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander- Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-2474
21. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Nonalcoholic steatohepatitis clinical research network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-1321
22. Koteish A, Diehl AM. Animal model of steatohepatitis. Best Pract Res Clin Gastroenterol 2002;16(5):679-690
23. Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 2009;9:299-314.
24. Pessin JE, Saltiel AR. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 2000; 106:165-169
25. Virkamäki A, Ueki K, Kahn CR. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 1999;103:931-933
26. Akiba Y, Takahashi K, Kimura M, Hirama SI, Matsumoto T. The influence of environmental temperature, thyroid status and a synthetic oestrogen on the induction of fatty livers in chicks. Br Poult Sci 1983;24:71-80.
27. Rivkees SA, Mattison DR. Ending propylthiouracil-induced liver failure in children. N Engl J Med 2009;360:1574-1575
28. Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004;10:1018-1023
29. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006;444:860-867
30. SerinoM,MenghiniR, FiorentinoL,AmorusoR,MaurielloA, Lauro D, et al. Mice heterozygous for tumor necrosis factor-a converting enzyme are protected from obesity-induced insulin resistance and diabetes. Diabetes 2007;56:2541-2546
31. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6:772-783